tda200 ht nano-sizing system (Paraytec Inc)
90
Structured Review
Paraytec Inc
tda200 ht nano-sizing system
Tda200 Ht Nano Sizing System, supplied by Paraytec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tda200+ht+nano-sizing+system/tda200+ht+nano+sizing+system/pm23751342-67-8-12
Average 90 stars, based on 1 article reviews
Tda200 Ht Nano Sizing System, supplied by Paraytec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tda200+ht+nano-sizing+system/tda200+ht+nano+sizing+system/pm23751342-67-8-12
Average 90 stars, based on 1 article reviews
tda200 ht nano-sizing system - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Taylor Dispersion Analysis Compared to Dynamic Light Scattering for the Size Analysis of Therapeutic Peptides and Proteins and Their Aggregates Article Snippet: TDA was performed on a TDA200 HT nano-sizing Dispersion:Article Title: A Taylor dispersion analysis method for the sizing of therapeutic proteins and their aggregates using nanolitre sample quantities. Article Snippet: The growing number of Biosimilars now being approved for development lends the need to develop new analytical techniques for rapid, cost effective analysis of these high value biotherapeutics.. The presence of aggregates in biopharmaceutical products is undesirable for many reasons.. A major concern is the potential immunogeneic response that aggregates can induce on administration. Article Title: Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering. Article Snippet: Biosimilar pharmaceuticals are complex biological molecules that have similar physicochemical properties to the originator therapeutic protein.. They are produced by complex multi-stage processes and are not truly equivalent.. Therefore, for a biosimilar to be approved for market it is important to demonstrate that the biological product is highly similar to a reference product. |